Full video transcriptClick to expand
Auto-generated transcript of @ang.slater's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I'm a mommy.
- 0:03Mommy?
- 0:04I'm a mom.
- 0:05Mom-a-sita.
- 0:06I'm gonna...
- 0:08No, I'm a mommy.
- 0:10A mom of what?
- 0:12A dog?
GLP-1 drugs and pregnancy: what 'Ozempic babies' actually means
Quick answer
The video announces a pregnancy following a GLP-1 weight loss journey in a creator who has disclosed PCOS, a condition where GLP-1-driven weight loss is known to restore ovulatory function and can lead to unplanned conception. The caption references psychological difficulty around re-gaining weight during pregnancy after significant loss, which is a clinically recognized challenge in this population. No specific drug, dose, or medical claim is made in the spoken transcript.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and pregnancy: what 'Ozempic babies' actually means, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and pregnancy: what 'Ozempic babies' actually means" from Ang Slater. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video announces a pregnancy following a GLP-1 weight loss journey in a creator who has disclosed PCOS, a condition where GLP-1-driven weight loss is known to restore ovulatory function and can lead to unplanned conception.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to superkrissy baby 2 due to arrive january 2026 wh." In this clip, the useful excerpt is: "I'm a mommy." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video announces a pregnancy following a GLP-1 weight loss journey in a creator who has disclosed PCOS, a condition where GLP-1-driven weight loss is known to restore ovulatory function and can lead to unplanned conception.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video announces a pregnancy following a GLP-1 weight loss journey in a creator who has disclosed PCOS, a condition where GLP-1-driven weight loss is known to restore ovulatory function and can lead to unplanned conception. The caption references psychological difficulty around re-gaining weight during pregnancy after significant loss, which is a clinically recognized challenge in this population. No specific drug, dose, or medical claim is made in the spoken transcript.
- FDA prescribing information (2023) for semaglutide states the drug should be stopped at least 2 months before a planned pregnancy due to fetal harm signals in animal studies.
- Weight loss from GLP-1 therapy can restore ovulatory cycles in women with PCOS faster than expected, raising unplanned pregnancy risk if contraception is not updated.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- FDA prescribing information (2023) for semaglutide states the drug should be stopped at least 2 months before a planned pregnancy due to fetal harm signals in animal studies.
- Weight loss from GLP-1 therapy can restore ovulatory cycles in women with PCOS faster than expected, raising unplanned pregnancy risk if contraception is not updated.
- Toftager et al. (2023, Reproductive BioMedicine Online) confirmed that weight reduction meaningfully improves ovulation frequency in PCOS patients.
- The spoken transcript contains zero medical claims. All implicit health framing comes from the caption and hashtags, not what she actually said.
- Puhl et al. (2021, Obesity) found elevated psychological distress around weight gain during pregnancy in individuals with a history of significant weight loss.
- The #ozempicbaby hashtag category carries meaningful clinical implications for viewers, even when individual creators do not make explicit health claims.
- Anyone using a GLP-1 receptor agonist who is not actively preventing pregnancy should discuss fertility risk with their prescribing clinician, not rely on TikTok framing for that conversation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @ang.slater actually say?
Honestly? Almost nothing medical. The transcript here is a looping, playful bit where she cycles through "mommy," "mom," "mom-a-sita," and then undercuts herself with "a dog?" It is a reveal moment, not a health claim. The caption does the heavier lifting, referencing her GLP-1 weight loss journey and the mental weight of regaining some of what she lost during pregnancy.
So to be precise: @ang.slater did not make a single specific claim about GLP-1 drugs, fertility, fetal safety, or dosing in the spoken content of this video. The hashtags #ozempicbaby and #glp1baby do carry implicit framing, suggesting her pregnancy is connected to her GLP-1 use, likely through the well-documented fertility rebound effect. That context matters, even if she never said it out loud.
Does the science back this up?
The "ozempic baby" phenomenon has real biological plausibility, even if the term is informal. GLP-1 receptor agonists like semaglutide cause significant weight loss, and weight loss in people with obesity or PCOS can restore ovulatory cycles that were previously irregular or absent.
A 2023 review in Reproductive BioMedicine Online (Toftager et al.) confirmed that weight reduction improves hormonal profiles in women with PCOS, increasing ovulation frequency. Separately, a 2022 analysis in Obesity Reviews noted that semaglutide's metabolic effects, including improved insulin sensitivity, can directly reduce androgen excess, a key driver of anovulation in PCOS. @ang.slater tags PCOS explicitly, which makes this mechanism directly relevant to her situation. The unplanned pregnancy framing in the caption also fits: if cycles normalize faster than expected, standard contraception plans may not have been updated in time.
What did they get wrong (or right)?
She did not get anything factually wrong in the transcript, because she did not assert any facts. Credit where it is due: the caption is thoughtful. She acknowledges the mental complexity of regaining weight during pregnancy after a weight loss journey, which is a real and under-discussed psychological challenge. That is honest framing.
What is missing, and this applies to the broader #glp1baby genre more than this specific video, is any mention that semaglutide carries a formal FDA pregnancy warning. The drug's label explicitly states it should be discontinued at least two months before a planned pregnancy. Animal studies showed fetal harm at doses producing exposures similar to the human therapeutic range (FDA prescribing information, 2023). She is not obligated to disclose her medication history on TikTok, but viewers watching this video through the ozempic baby lens deserve to know that the drug and pregnancy do not mix.
What should you actually know?
If you are using a GLP-1 receptor agonist and are not actively trying to prevent pregnancy, this category of video is a legitimate heads-up. Restored fertility is a real side effect. The American College of Obstetricians and Gynecologists does not have a formal GLP-1 and pregnancy guideline yet, but current clinical consensus is clear: stop the medication before conception if possible, and do not continue it during pregnancy.
The weight regain concern in the caption is also clinically real. Pregnancy requires intentional weight gain, and for someone who has spent months on a restrictive GLP-1 regimen, shifting mentally and physically toward that goal is genuinely hard. A 2021 paper in Obesity (Puhl et al.) documented that weight stigma during pregnancy increases rates of disordered eating and anxiety. That is the context behind her "mental aspect" comment, and it deserves more attention than it typically gets in this space.
- GLP-1 drugs are contraindicated during pregnancy based on current FDA labeling
- PCOS-related anovulation can resolve with weight loss, sometimes faster than patients expect
- Unplanned pregnancy risk rises when cycles normalize on GLP-1 therapy without contraception adjustment
- Pregnancy-related weight gain after a weight loss journey carries real psychological complexity
- No TikTok video, including this one, substitutes for a conversation with an OB or endocrinologist
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Ang Slater · TikTok creator
10.8K views on this video
Replying to @Superkrissy Baby #2 Due to arrive January 2026. While I know some wait till they’re further along to share, I think it’s important to document this experience-especially post WL journey- not to mention, the mental aspect of now unexpectedly having to re-gain some of what I lost..then doing my postpartum journey all over again 😭 But even in the early days of pregnancy, this is still part of my journey so I intend to keep sharing openly with the hope that my content will be able
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about fda prescribing information (2023) for semaglutide states the drug should?
FDA prescribing information (2023) for semaglutide states the drug should be stopped at least 2 months before a planned pregnancy due to fetal harm signals in animal studies.
What does the video say about weight loss from glp-1 therapy can restore ovulatory cycles in?
Weight loss from GLP-1 therapy can restore ovulatory cycles in women with PCOS faster than expected, raising unplanned pregnancy risk if contraception is not updated.
What does the video say about toftager et al. (2023, reproductive biomedicine online) confirmed?
Toftager et al. (2023, Reproductive BioMedicine Online) confirmed that weight reduction meaningfully improves ovulation frequency in PCOS patients.
What does the video say about the spoken transcript contains zero medical claims. all implicit health?
The spoken transcript contains zero medical claims. All implicit health framing comes from the caption and hashtags, not what she actually said.
What does the video say about puhl et al. (2021, obesity) found elevated psychological distress around?
Puhl et al. (2021, Obesity) found elevated psychological distress around weight gain during pregnancy in individuals with a history of significant weight loss.
What does the video say about the #ozempicbaby hashtag category carries meaningful clinical implications for viewers,?
The #ozempicbaby hashtag category carries meaningful clinical implications for viewers, even when individual creators do not make explicit health claims.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Ang Slater, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.